International Stem Cell CORP financial data

Symbol
ISCO on OTC
Industry
Pharmaceutical Preparations
Location
9745 Businesspark Avenue, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
BTHC III INC. (to 1/19/2007)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 73.8 % +2.99%
Quick Ratio 27.3 % -2.5%
Debt-to-equity -126 % +1.53%
Return On Equity 16.4 %
Return On Assets -12.6 % -297%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8M shares 0%
Common Stock, Shares, Outstanding 8M shares 0%
Entity Public Float 481K USD -68.6%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 8M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 8M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.53M USD +2.38%
Cost of Revenue 3.64M USD +5.3%
Research and Development Expense 613K USD +30.4%
Selling and Marketing Expense 1.25M USD +4.96%
General and Administrative Expense 3.57M USD +5.24%
Costs and Expenses 9.07M USD +6.62%
Operating Income (Loss) -543K USD -205%
Nonoperating Income (Expense) -135K USD -126%
Net Income (Loss) Attributable to Parent -678K USD -294%
Earnings Per Share, Basic -0.07 USD/shares -800%
Earnings Per Share, Diluted -0.07 USD/shares -800%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 680K USD +5.59%
Inventory, Net 1.38M USD +5.09%
Other Assets, Current 10K USD -37.5%
Assets, Current 3.49M USD -4.59%
Property, Plant and Equipment, Net 290K USD +19.3%
Operating Lease, Right-of-Use Asset 407K USD -32.5%
Intangible Assets, Net (Excluding Goodwill) 739K USD -9.55%
Assets 5.18M USD -8.17%
Accounts Payable, Current 321K USD +5.94%
Accrued Liabilities, Current 475K USD +7.47%
Liabilities, Current 4.72M USD +0.77%
Operating Lease, Liability, Noncurrent 203K USD -60.8%
Liabilities 4.92M USD -5.37%
Retained Earnings (Accumulated Deficit) -111M USD -0.62%
Stockholders' Equity Attributable to Parent -4.04M USD -4.72%
Liabilities and Equity 5.18M USD -8.17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -193K USD -189%
Net Cash Provided by (Used in) Financing Activities 250K USD -69.7%
Net Cash Provided by (Used in) Investing Activities -9K USD +40%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 8M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -202K USD -200%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.31M USD -8.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3K USD 0%
Deferred Tax Assets, Valuation Allowance 7.86M USD -65.7%
Deferred Tax Assets, Gross 8.02M USD -65.4%
Operating Lease, Liability 518K USD -33.7%
Payments to Acquire Property, Plant, and Equipment 8K USD -46.7%
Lessee, Operating Lease, Liability, to be Paid 567K USD -37.8%
Property, Plant and Equipment, Gross 2.63M USD +3.38%
Operating Lease, Liability, Current 315K USD +19.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 119K USD -66.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 360K USD +3.15%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49K USD -62.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 119K USD -66.9%
Deferred Tax Assets, Operating Loss Carryforwards 5.48M USD -71.6%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 478K USD -49.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 118K USD -67.2%
Additional Paid in Capital 107M USD +0.47%
Amortization of Intangible Assets 83K USD +1.22%
Depreciation, Depletion and Amortization 49K USD -3.92%
Deferred Tax Assets, Net of Valuation Allowance 157K USD -26.3%
Share-based Payment Arrangement, Expense 496K USD +12%
Interest Expense 139K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%